PetVivo Holdings, Inc. (PETV)
| Market Cap | 25.83M +12.3% |
| Revenue (ttm) | 1.18M -9.5% |
| Net Income | -9.87M |
| EPS | -0.30 |
| Shares Out | 37.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.6300 |
| Previous Close | 0.6800 |
| Day's Range | 0.6300 - 0.6300 |
| 52-Week Range | 0.5899 - 1.6900 |
| Beta | 1.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About PetVivo Holdings
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company’s lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. The company is based in Edina, Minnesota. [Read more]
Financial Performance
In fiscal year 2026, PetVivo Holdings's revenue was $1.14 million, an increase of 0.80% compared to the previous year's $1.13 million. Losses were -$10.47 million, 24.7% more than in 2025.
Financial StatementsNews
PetVivo changes name of Cosmeta subsidiary to Somatrix
PetVivo (PETV) Holdings announced that its subsidiary, Cosmeta Corp., has changed its name to Somatrix Technologies. The new name reflects the Company’s strategic vision for Somatrix as a dedicated hu...
PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION
New Human Health Subsidiary to Advance Development of Innovative Biomaterial Technologies and Potential New Products for Human and Animal Health
PetVivo Holdings Slides: Investor presentation
PetVivo Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 20, 2026.
PetVivo Holdings Earnings Call Transcript: Q1 2027
Revenue grew 13% year-over-year and 33% sequentially, driven by SPRYNG product focus and expanded sales force. The PBM acquisition and PetVivo.ai platform advance R&D and digital health, while Health Canada approval opens the Canadian market. Gross margins are expected to rise as sales shift fully to proprietary products.
PetVivo Holdings Quarterly report: Q1 2027
PetVivo Holdings has published its Q1 2027 quarterly earnings report on August 14, 2026.
PetVivo Holdings Earnings release: Q1 2027
PetVivo Holdings released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027
MINNEAPOLIS, MN, US, Aug. 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI...
PetVivo Sets Fiscal First Quarter 2027 Conference Call for Friday, August 14, 2026 at 5:00 p.m. ET
MINNEAPOLIS, MN, US, Aug. 07, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), an emerging biomedical company delivering innovative medical devices and therapeutics for equ...
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP ® Product Line MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) worki...
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minnea...
PetVivo Holdings Earnings Call Transcript: Q4 2026
Fiscal 2026 saw modest revenue growth, major product and technology launches, and strategic acquisitions, despite a wider net loss driven by lower-margin product sales and impairment charges. Regulatory milestones and new AI-powered platforms position the company for accelerated growth in expanding markets.
PetVivo Holdings Annual report: Q4 2026
PetVivo Holdings has published its Q4 2026 annual report on June 29, 2026.
PetVivo Holdings Earnings release: Q4 2026
PetVivo Holdings released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
PetVivo Reports Financial and Operational Results for Fiscal 2026
MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc....
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc....
PetVivo Holdings Transcript: Life Sciences Virtual Investor Forum
The presentation highlighted innovative joint health products, a soon-to-launch AI platform, and strategic acquisitions to expand both animal and human health pipelines. Key milestones include Canadian market entry, new clinical studies, and human FDA filings by 2027.
PetVivo Holdings Announces Transformative Acquisition Of PiezoBioMembrane To Build a Leading Functional Biomaterials Platform
Acquisition Strengthens Company's Intellectual Property Portfolio and Creates New Opportunities for Medical Device and Therapeutic Product Development Across Animal and Human Health Markets
PetVivo Holdings, Inc. to Present at the Life Sciences Investor Forum on June 24th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
PetVivo Holdings Transcript: Investor update
Innovative joint health solutions are gaining traction among veterinarians, with Spryng and PrecisePRP offering multimodal, less invasive alternatives to traditional treatments. Strategic distribution partnerships and upcoming clinical milestones are set to drive further adoption and market expansion.
PetVivo selects New to The Street for national T.V. commercials
New to The Street announced that PetVivo (PETV) Holdings has expanded its relationship with the media platform through an awareness campaign featuring national television commercials. The expanded cam...
PetVivo Holdings, Inc. to Host Virtual Investor Event
Virtual investor event scheduled for Tuesday, June 16, 2026, at 1 p.m. ET MINNEAPOLIS, MN, US, June 08, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation wit...
PetVivo Holdings, Inc. to Present at the Market Movers Investor Summit
Minneapolis, Minnesota--(Newsfile Corp. - April 21, 2026) - PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVi...
PetVivo Holdings Slides: Corporate presentation
PetVivo Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
PetVivo Holdings Earnings Call Transcript: Q3 2026
Strategic alliances and new product launches drove platform advancement, with PetVivo AI showing strong early results and creating a high-margin recurring revenue stream. Revenues dipped 2% year-over-year, but gross margin remained robust at 62.2%.
PetVivo Holdings Earnings release: Q3 2026
PetVivo Holdings released its Q3 2026 earnings on February 17, 2026, summarizing the period's financial results.